Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyReferences
- Heart disease and stroke statistics–2011 update: a report from the American Heart Association.Circulation. 2011; 123: e18-e209
- Platelet activation and atherothrombosis.N Engl J Med. 2007; 357: 2482-2494
- Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.Chest. 2012; 141: e89S-e119S
- Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.Chest. 2012; 141: e637S-e668S
- ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).Eur Heart J. 2011; 32: 2999-3054
- 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non–ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.J Am Coll Cardiol. 2012; 60: 645-681
- Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology.Eur Heart J. 2008; 29: 2909-2945
- 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.Circulation. 2009; 120: 2271-2306
- Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.Chest. 2012; 141: 7S-47S
- Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006.JAMA. 2007; 297: 1892-1900
- The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein.J Clin Invest. 1975; 56: 624-632
- Low-dose aspirin for the prevention of atherothrombosis.N Engl J Med. 2005; 353: 2373-2383
- Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.Lancet. 1988; 2: 349-360
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.Lancet. 2009; 373: 1849-1860
- A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease.Eur Heart J. 2006; 27: 2667-2674
- Seeking the optimal aspirin dose in acute coronary syndromes.Am J Cardiol. 2002; 90: 622-625
- Aspirin dose for the prevention of cardiovascular disease: a systematic review.JAMA. 2007; 297: 2018-2024
- Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition).Chest. 2008; 133: 199S-233S
- P2Y12, a new platelet ADP receptor, target of clopidogrel.Semin Vasc Med. 2003; 3: 113-122
- Prasugrel.Circulation. 2010; 122: 394-403
- The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin.Drug Metab Dispos. 2003; 31: 53-59
Plavix (clopidogrel) prescribing information. Available at: http://products.sanofi.us/plavix/plavix.html (last accessed March 14, 2012).
Plavix (clopidogrel) summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000174/WC500042189.pdf (last accessed March 14, 2012).
- Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.N Engl J Med. 2001; 345: 494-502
- Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.Circulation. 2003; 108: 1682-1687
- Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.N Engl J Med. 2005; 352: 1179-1189
- Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.Lancet. 2005; 366: 1607-1621
- Prasugrel versus clopidogrel in patients with acute coronary syndromes.N Engl J Med. 2007; 357: 2001-2015
Effient (prasugrel) prescribing information. Available at: http://pi.lilly.com/us/effient.pdf (last accessed March 14, 2012).
Effient (prasugrel) summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000984/WC500021971.pdf (last accessed March 14, 2012).
Eli Lilly and Company. Cardiovascular and Renal Drugs Advisory Committee briefing document. Effient (Prasugrel). Acute coronary syndromes managed by percutaneous coronary intervention. Available at: http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4412b1-03-Lilly.pdf (last accessed October 12, 2012).
- Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation.J Thromb Haemost. 2009; 7: 1556-1565
- Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist.Cardiovasc Ther. 2009; 27: 259-274
Brilinta (ticagrelor) prescribing information. Available at: http://www1.astrazeneca-us.com/pi/brilinta.pdf (last accessed March 13, 2012).
Brilique (ticagrelor) summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001241/WC500100494.pdf (last accessed March 13, 2012).
- Ticagrelor versus clopidogrel in patients with acute coronary syndromes.N Engl J Med. 2009; 361: 1045-1057
- Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (PLATO) trial.Circulation. 2011; 124: 544-554
- Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.Am Heart J. 2009; 157: 599-605
- Secondary prevention of vascular disease by prolonged antiplatelet treatment.Br Med J (Clin Res Ed). 1988; 296: 320-331
- The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials.Br J Clin Pharmacol. 1993; 35: 219-226
- Collaborative overview of randomised trials of antiplatelet therapy–I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.BMJ. 1994; 308: 81-106
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.BMJ. 2002; 324: 71-86
- ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.Circulation. 2008; 118: 1894-1909
- Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury.Ann Intern Med. 1994; 120: 184-189
- Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.N Engl J Med. 2010; 363: 930-942
- Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy.Circulation. 2008; 117: 192-199
- Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.J Clin Invest. 1982; 69: 1366-1372
- Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials.Am Heart J. 2011; 162: 115-124
- Aspirin.Circulation. 2000; 101: 1206-1218
- Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative.Am J Cardiol. 2007; 99: 1496-1499
- Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study.Eur Heart J. 2009; 30: 900-907
AstraZeneca. Ticagrelor NDA 22-433 briefing document for cardiovascular and renal drug advisory committee meeting. Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm220197.pdf (last accessed October 12, 2012).
- Anti-platelet therapy: cyclooxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy.Br J Clin Pharmacol. 2011; 72: 619-633
- Anti-platelet effects of aspirin vary with level of P2Y(12) receptor blockade supplied by either ticagrelor or prasugrel.J Thromb Haemost. 2011; 9: 2103-2105
- Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal anti-inflammatory drugs after acute myocardial infarction.Circulation. 2006; 113: 2906-2913
- In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation.J Thromb Haemost. 2011; 9: 552-561
- 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Circulation. 2011; 123: 2022-2060
- ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction).J Am Coll Cardiol. 2004; 44: E1-E211
Article Info
Publication History
Footnotes
The author did not receive any financial compensation for authoring this article. Medical writing support was funded by AstraZeneca .
See page 743 for disclosure information.